Cytokinetics, Inc. (CYTK) Posts Surprise Q4 Profit; Issues Solid Outlook
Tweet Send to a Friend
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q4 EPS of $0.21, $0.29 better than the analyst estimate of ($0.08). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
